Is the new “energetic” feedback for insulin delivery monitoring available in any acute severe glucose metabolism disorders?

Abstract

Background: Taking into account the remaining difficulties of managing insulin delivery without hypoglycaemia and yo-yo events, a new feedback based on differential temperature evaluation ($\Delta T$) was previously proposed and successfully tested with a device named ADD-CIT (apparatus-for-diabetes-diagnosis-complex-for-insulin-therapy) on acute decompensated Diabetes 1 patients. The present work aim is to verify whether ADD-CIGT can be useful for insulin delivery management in any acute severe hyperglycaemia independently on its origin.

Material and methods: Three groups of patients were considered: DM-1 (83), DM-2 (45) and without known diabetes DM-0 (66). In each group part of patients was treated as usually (UT), part-by ADD-CIT. Healthy volunteers (15) underwent body temperature observation for determination of its normal evolution. Glycaemia was measured once/hour (gasometer or prickle method). Differential body temperatures were registered by the device.

Results: In the ADD-CIT subgroups a 30-40% glycaemia decrease from its initial value was observed within 2-4 hours versus 5-7 hours in the UT subgroups. Episodes of hypoglycaemia ($<$4.3 mMole/l) were registered in 15% of the ADD-CIT sessions (10 patients, all DM1), versus 22.5% in the UT subgroups. Yo-yo phenomena were exceptional in ADD-CIT subgroups and frequent in UT. $\Delta T$ reactions occurred about 1 hour before glycaemia ones that might explain the better adaptation of insulin delivery to the patient’s needs in ADD-CIT subgroups than in UT ones. $\Delta T$ levels approaching value was observed within 2-4 hours versus 5-7 hours in the UT subgroups. Episodes of hypoglycaemia (<4.3 mMole/l) were registered in 15% of the ADD-CIT sessions (10 patients, all DM1), versus 22.5% in the UT subgroups. Yo-yo phenomena were exceptional in ADD-CIT subgroups and frequent in UT. $\Delta T$ reactions occurred about 1 hour before glycaemia ones that might explain the better adaptation of insulin delivery to the patient’s needs in ADD-CIT subgroups than in UT ones. $\Delta T$ levels approaching value was observed within 2-4 hours versus 5-7 hours in the UT subgroups. Episodes of hypoglycaemia (<4.3 mMole/l) were registered in 15% of the ADD-CIT sessions (10 patients, all DM1), versus 22.5% in the UT subgroups. Yo-yo phenomena were exceptional in ADD-CIT subgroups and frequent in UT. $\Delta T$ reactions occurred about 1 hour before glycaemia ones that might explain the better adaptation of insulin delivery to the patient’s needs in ADD-CIT subgroups than in UT ones. $\Delta T$ levels approaching value was observed within 2-4 hours versus 5-7 hours in the UT subgroups. Episodes of hypoglycaemia (<4.3 mMole/l) were registered in 15% of the ADD-CIT sessions (10 patients, all DM1), versus 22.5% in the UT subgroups. Yo-yo phenomena were exceptional in ADD-CIT subgroups and frequent in UT. $\Delta T$ reactions occurred about 1 hour before glycaemia ones that might explain the better adaptation of insulin delivery to the patient’s needs in ADD-CIT subgroups than in UT ones. $\Delta T$ levels approaching value was observed within 2-4 hours versus 5-7 hours in the UT subgroups. Episodes of hypoglycaemia (<4.3 mMole/l) were registered in 15% of the ADD-CIT sessions (10 patients, all DM1), versus 22.5% in the UT subgroups. Yo-yo phenomena were exceptional in ADD-CIT subgroups and frequent in UT. $\Delta T$ reactions occurred about 1 hour before glycaemia ones that might explain the better adaptation of insulin delivery to the patient’s needs in ADD-CIT subgroups than in UT ones. $\Delta T$ levels approaching value was observed within 2-4 hours versus 5-7 hours in the UT subgroups.

Conclusion: The ADD-CIT patients have shown faster glycaemia decrease and stabilization, less hypoglycaemia events than UT patients independently on hyperglycaemia causes. This supports the hypothesis that $\Delta T$ evolution registration is useful as a complementary feedback for insulin delivery management in any patients with acute severe hyperglycaemia.

Keywords: diabetes mellitus, insulin therapy, glucose metabolism disorders, energetic balance, artificial pancreas

Abbreviations: ADD-CIT, apparatus for diabetes diagnosis and complex for insulin therapy; ARCA, Acute cardio-respiratory arrest; BW, body weight; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; DM0, non-diabetic patients; $\Delta T$, difference between core and superficial temperatures; HD, heart disease; ICU, Intensive Care Unit; Tc, core temperature; Ts, superficial temperature; UT, Usual treatment

Introduction

Up to now glycaemia measure remains the only criterion used for the treatment management of hyperglycaemia in diabetic or critically ill (ARDS, shock) patients and in spite of interesting innovations including gluconag administration, artificial pancreas, close loop use and others, hypoglycaemia episodes and yo-yo events are still a problem during insulin therapy.\(^1\)\(^-\)\(^6\) According to some authors\(^7\)\(^-\)\(^9\) and our previous observations, glycaemia reaction is too slow to reflect the real metabolism situation. Hence the correction is started a little late, excessive doses administration and answers to them cannot be avoided, even if mathematic anticipation is provided, and that cause the aforementioned events.\(^7\)\(^-\)\(^9\)

Besides, glycaemia is known to be the result of the difference between glucose production and utilization which depend on many changing factors, such as external glucose intake, internal hormonal influences, neo gluconeogenesis, physical and intellectual activities. Taking into account that 70% of the energy used by the organism comes from glucose turn over\(^10\) it was likely that the basal metabolism evolution could better reflect the organism needs in insulin and glucose than glycaemia measure, allowing anticipation of its fluctuations. But presently, direct basal metabolism measure is no more performed and not even feasible in current clinics. Indirect representation of the energetic balance evolution, based on the dynamics of the difference between the body core temperature and the temperature of the body superficial layers, has seemed possible.

Some years ago an alternative feedback for insulin delivery monitoring was proposed.\(^11\)\(^-\)\(^12\)
Is the new “energetic” feedback for insulin delivery monitoring available in any acute severe glucose metabolism disorders?

The hypothesis was that continuous record of $\Delta T$, (differential temperature $\Delta T$=core temperature $T_c$–superficial temperature $T_s$) represents the result of energy production and utilization, thus reflects glucose metabolism, and hence can be a valuable complement to blood glucose measure for monitoring insulin therapy. Devices were created and tested which used $\Delta T$ evolution as a feedback for automated insulin delivery.

Recently the Apparatus for Diabetes Diagnosis coupled with Complex for Insulin Therapy (ADD-CIT), using this kind of feedback has been shown to be useful in the treatment monitoring of acute life threatening alterations of the glucose metabolism due to type 1 diabetes. But is it able to correct glucose metabolism disorders of other origin that is in any acute situation of hyperglycaemia?

The objective of the present work is to verify the assertion that ADD-CIT could be successfully used in any severe, acute glucose metabolism disorders when insulin treatment is required, temporarily or not, in different groups of diabetic and non-diabetic patients.

### Material and Methods

Three groups of patients were considered: with type 1 diabetes (DM-1-83); with type 2 diabetes (DM-2-45); and patients without known diabetes (DM-0-66) but presenting a severe pathology also causing acute hyperglycaemia difficult to control. The evolution of glycaemia and $\Delta T$ was also investigated in a group of 15 healthy volunteers.

Part of these patients were treated according usual schemas (UT), the other part was treated by ADD-CIT (Table 1). The main inclusion criterion was the presence of hyperglycaemia > 11.1 mmol/l (200 mg/dl) at admission. The request of the treating physician was also necessary. Exclusion criteria were: age <16, gravidity, rectal pathology, Age, sex, BW were comparable. Observation or treatment session duration was 2-5 hours as a rule, exceptionally up to 8 hours, and always provided under the supervision of an experimented ICU physician. The device and its use were previously described\textsuperscript{(15, 16)} (Figure 1).

### Table 1 Patient cohort

<table>
<thead>
<tr>
<th>Series</th>
<th>DM 1</th>
<th>DM 2</th>
<th>DM 0</th>
<th>Healthy control</th>
</tr>
</thead>
<tbody>
<tr>
<td>A D D - C I T</td>
<td>64 (including 50 with kidney insufficiency)</td>
<td>36 (including 18 with heart pathology)</td>
<td>27 (with heart pathology)</td>
<td>15 (observation only)</td>
</tr>
<tr>
<td>treated (N=142)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Usual schema</td>
<td>19</td>
<td>9</td>
<td>39 (24 ARCA, 15 with heart pathology)</td>
<td>0</td>
</tr>
<tr>
<td>(N=67)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>83</td>
<td>45</td>
<td>66</td>
<td>15</td>
</tr>
</tbody>
</table>

### Figure 1 ADD-CIT design schema:

1: Rectal catheter with double thermic sensors. 2: Analyzer bloc for $\Delta T$ evaluation. 3: Computer with pump program. 4: Insulin pump.

### For reminding 1. Description of the device

The rectal catheter (1) enclosed into a thin, hermetic, waterproof and one-using polyethylene membrane, has a 4mm diameter and 8 cm length. The two temperature sensors are at 4.5 cm from each other to avoid temperature “contamination” between them. When the catheter is introduced, the inner sensor at its top is placed at the level of the deep haemorrhoidal venous plexus and registers the core temperature ($T_c$) reflecting thermogenesis; the lower sensor is placed just above the external anal sphincter and reflects the superficial temperature ($T_s$) of the subcutaneous para-rectal fat.

The sensors data are cabled to an analyser (2) which calculates $\Delta T$ and the information is delivered to a computer (3). The evolution of $\Delta T$ is used for the elaboration of a program which is transmitted by the computer to an insulin pump (4) adapted in consequence. Insulin–Actrapid or Humulin, that is of rapid action, diluted to 20 or 40 UI/ml, is delivered through a short (<20 cm) catheter to the patient venous access to avoid insulin adsorption and degradation. Insulin delivery might be operator programmed (30 impulses/min usually during 30 minutes at the session beginning while sensors adapt) or automatized according to $\Delta T$ values evolution. 1 impulse of the pump represents from 0.0003 to 0.001 UI according to the insulin pre dilution. The program regulates the number of impulses/min. A visual control of the $\Delta T$, $T_c$ and $T_s$ ciphers, and insulin delivery impulses was ensured through the computer.

### 2. Description of the procedure

The investigations were provided in a hospital (ICU) room at temperature $21\pm 1^\circ C$, under the permanent observation and responsibility of an intensive care physician after receiving the patient’s own informed consent or his family’s. The responsible physician mildly introduced the catheter with the sensors into rectum at a depth of 6.5 cm (mark on the catheter). An intravenous connection was placed independent on the patient injection system or connected with it for intravenous insulin providing. Usually patients did not receive any food except in the case when session duration exceeded 4 hours and the patient was conscious. In the last case standard hospital meal was delivered.

At the end of the session, rectal catheter was carefully taken out the organism and pump insulin delivering - removed. The session might be interrupted in the case of emergency procedures, defecation or disagreeable anal feelings (the last was not observed in this trial). Criteria for ending a session were objective significant decrease of blood glucose level (<11.1mm/l) and $\Delta T >0.05^\circ C$ with subjective improvement of the patient’s condition. After ADD or ADD-CIT procedure patients returned to ICU responsibility or were transferred through the computer.

### Citation

Is the new “energetic” feedback for insulin delivery monitoring available in any acute severe glucose metabolism disorders?

As far as glycaemia is the universal criterion of severity and treatment of hyperglycaemia, it was used here for control of the device work. Evaluation of the capillary glycaemia was performed once an hour by strip method (One Touch, Switzerland or Acutrend, USA) and controlled each 3 hours by arterial glucometer ("ADL-90 Flex“ or “Glucose and lactate Analyser”, Eco Basic United, Moskau). Usual in ICU clinical investigations were provided.

Glycaemia was considered as normal if included between 3.88 and 7.7 mM/l (70 and 140 mg/dl), increased but acceptable between 7.71 and 11.1 mM/dl (141 and 200 mg/dl), moderately high between 11.1 and 15.0 (200 and 270 mg/l); high between 15.1 and 20.0mM/l (270 and 360 mg/dl); very high between 20.1 and 25.0 (360 and 450 mg/dl); threatening high >25.1 (>450 mg/dl). Maximum observed was 33 mM/l (599.4, i.e. 600 mg/dl).

∆T < 0.05 and >0.2°C was considered as pathological NB. ∆T at hour 0 that is at the moment of introducing the rectal catheter cannot be registered because a 30 min time is necessary for adaptation of thermic sensors to organism conditions.

Table 2 Hypoglycaemia episodes in patients treated with ADD-CIT use or classical method

<table>
<thead>
<tr>
<th>Series</th>
<th>ADD-CIT (N)</th>
<th>Classical method</th>
<th>ADD-CIT/CM (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sessions</td>
<td>Events</td>
<td>Patients</td>
</tr>
<tr>
<td>DM 1 )</td>
<td>89</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>DM 2</td>
<td>16</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>DM 0 (HD)</td>
<td>26</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TOTAL</td>
<td>131</td>
<td>20</td>
<td>13</td>
</tr>
</tbody>
</table>

Figure 2 Graphics of glycaemia evolution in different patient groups treated with classical feedback and insulin delivery schemas versus with ADD-CIT. Series 1–blue–Type 1 Diabetes, Series 2–red–Type 2 Diabetes, series 3–green–Heart failure in non-diabetic patients ((M ± SD):

Comparison of ADD-CIT groups with Classical treatment groups Evaluation of the ADD-CIT and classical treatment in each of the three pathologies represented.

Citation: Novikov VK, Dobos SA, Devriendt J, et al. Is the new “energetic” feedback for insulin delivery monitoring available in any acute severe glucose metabolism disorders? Endocrinol Metab Int J. 2018;6(5):318–322. DOI: 10.15406/emij.2018.06.00205
In the control groups monitored only by glycaemia evaluation, the same glycaemia decrease was attained only after 5-7 hours with frequent yo-yo phenomena even concerning mean values (Figure 2A) (Figure 2B). Significant hypoglycaemia events were also present during the 67 provided sessions: they represented 22.4% of the sessions and concerned 14.9% of the patients. The phenomena affected the 3 groups of patients.

Considering the different pathologies ADD-CIT ensured a regular mild glycaemia decrease with following stabilisation at an acceptable level (average between 140 and 200 mg/dl) in DM 1 and DM 2 patients, whereas in HD DM0 patients the results were less demonstrative: average glycaemia remained moderately high (about 250 mg/dl) at the end of the sessions. Classical treatment also led to a glycaemia decrease, but more chaotic with temporary re-increases especially in DM 2 and HD DM 0 patients (Figure 2). The influence of pathology on the hypoglycaemia events in terms of patients concerned and event repetition in the same patient was different and affected mainly type 1 diabetes patients see Table 2.

It is to be noted that significant glycaemia average decrease could not be found because of the great dispersion of the registered values. It is the reason why the attention was concentrated on the individual percentage of the glycaemia decrease during the observation period in both subgroups.

No correlation was noted between ΔT and glycaemia in hyperglycaemic patients as well as in healthy persons, though in this last group during the fourth hour of observation the values of both indices decreased (Figure 3). ΔT values were negative mainly in decompensated DM 1 patients. ΔT decreased during the sessions in DM 2 patients but rarely reached negative levels. At the end of the most successful sessions ΔT values corresponded to values observed in healthy controls (Figure 3). This was an indication for stopping the session. In some cases ΔT abnormally felt at the end of a session whereas glycaemia remained stable: at this moment a cautious glucose injection usually has corrected the situation without glycaemia modification.

The insulin amount delivered in both groups was different: a little lower in the ADD-CIT. But as far as the patients have already received insulin before the sessions in different quantities, with different efficiency, it was difficult to appreciate the significance of the differences observed because the variability of the used doses was great in both series.

**Discussion**

Though our series were small and not fully matched, the mean results of insulin therapy in ADD-CIT groups of patients in terms of glycaemia decrease and stabilization as well as decrease of hypoglycaemia event frequency and repeats looked convincingly better than in patients treated by the usual procedure only based on glycaemia measurements. This confirms the usefulness of ΔT evolution evaluation as a complementary feedback for insulin delivery not only in DM 1 patients but also in DM 2 and any other patients with acute severe glucose metabolism disorders.

Interesting that the effect of both treatment techniques were slightly different depending on the kind of pathology concerned. ADD-CIT seemed to be more efficient in DM 1 than in DM 2 patients. On the contrary classical treatment has led to a certain stabilisation in DM 2 patient mean glycaemia though the last remained about 200 mg/dl. Heart disease DM0 patients were the more difficult to be helped. That means that ADD-CIT as any other insulin treatment of hyperglycaemia has its limits: as long as the causes of the disorder are not eliminated a relapse has to be awaited. It explains the situation with ARCA patients. So ADD-CIT is only an adapted correction of acute hyperglycaemia, because ΔT evolution is more sensible to metabolism variations than glycaemia: the reactions were noted within 1-2 min. instead of 30-40 min or even more. This is one is a probable explanations of the absence of correlation between glycaemia and ΔT.

The signification of isolated values of ΔT is not clear yet, though it is known that negative values are not a good prognosis, especially if they persist. In our retrospective study we also should have to take into account 1/ the former treatment which was administrated to the patients prior to the session beginning, 2/ the peculiarities of the basis pathology development (with complications or not and what kind of them), their possible influence on the present status and, consequently, on initial ΔT. So special investigations in that direction are worthwhile to be planned.

Some other questions remain: Is ΔT feedback applicable to chronic treatment of glucose metabolic disorders? To primary hypoglycaemia situations? And what may be the diagnostic or prognostic signification of ΔT levels and dynamics? The first variant of our device was ADD, that means it was created with a diagnosis aim.10-11 For realization of these verifications some technical progress is to be realized, particularly the telemetric measure of Tc and Ts.

**Conclusion**

The ADD-CIT device based on “energetic” feedback for insulin treatment monitoring is not worse and probably more adapted to patient individual approach than classical treatment schemas, and can be proposed in any acute severe hyperglycaemia.

**Acknowledgments**

The authors are thankful to Professor P Bergmann (ULB Laboratory of Experimental Medicine, Brussels, Belgium) for discussing the results and to TP Pisareva ( presently retreated, Moscow) for scientific and logistic help. They have appreciated the “ideological” support of Dr P Delrée and the Institute of Pathology and Genetics (Gosselies, Belgium).

---

**Citation:** Novikov VK, Dobos SA, Devriendt J, et al. Is the new “energetic” feedback for insulin delivery monitoring available in any acute severe glucose metabolism disorders? *Endocrinol Metab Int J.* 2018;6(5):318–322. DOI: 10.15406/emij.2018.06.00205
Conflict of interest

There is no conflict of interest.

References


Citation: Novikov VK, Dobos SA, Devriendt J, et al. Is the new “energetic” feedback for insulin delivery monitoring available in any acute severe glucose metabolism disorders? Endocrinol Metab Int J. 2018;6(5):318–322. DOI: 10.15406/emij.2018.06.00205